CervoMed Inc. Files 8-K with Regulatory Updates

TL;DR

CervoMed filed an 8-K on 10/8/25 covering Reg FD, other events, and financials. Formerly Diffusion Pharma.

AI Summary

CervoMed Inc. filed an 8-K on October 8, 2025, reporting on events including a Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits. The company, formerly known as Diffusion Pharmaceuticals Inc., RestorGenex Corp, and Stratus Media Group, Inc., is incorporated in Delaware and headquartered in Boston, MA.

Why It Matters

This filing provides crucial updates on CervoMed's regulatory compliance and financial reporting, which are important for investors to assess the company's current status and future prospects.

Risk Assessment

Risk Level: low — The filing is a routine 8-K reporting on standard corporate events and disclosures, not indicating any immediate material adverse changes.

Key Numbers

• 20251008 — Filing Date (Date of report and earliest event)

Key Players & Entities

• CervoMed Inc. (company) — Registrant
• Diffusion Pharmaceuticals Inc. (company) — Former company name
• RestorGenex Corp (company) — Former company name
• Stratus Media Group, Inc (company) — Former company name
• 001-37942 (company) — Commission File Number
• 30-0645032 (company) — I.R.S. Employer Identification No.
• 20 Park Plaza, Suite 424 Boston, Massachusetts 02116 (company) — Business Address

FAQ

Key Financial Figures

• $0.001 — on which registered Common Stock , $0.001 par value CRVO NASDAQ Capital Market

Filing Documents

• crvo20251008_8k.htm (8-K) — 32KB
• ex_867784.htm (EX-99.1) — 29KB
• logosmlr.jpg (GRAPHIC) — 4KB
• 0001437749-25-030719.txt ( ) — 203KB
• crvo-20251008.xsd (EX-101.SCH) — 3KB
• crvo-20251008_def.xml (EX-101.DEF) — 11KB
• crvo-20251008_lab.xml (EX-101.LAB) — 15KB
• crvo-20251008_pre.xml (EX-101.PRE) — 11KB
• crvo20251008_8k_htm.xml (XML) — 3KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure Press Release On October 8, 2025, CervoMed Inc. (the "Company," "we" or "us") issued a press release announcing new data from the RewinD-LB Phase 2b clinical trial of neflamapimod in patients with dementia with Lewy bodies ("RewinD-LB Trial"). A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein. Presentation Certain information concerning the business, clinical studies, development plans, financial position and related matters of the Company, including the new results from the RewinD-LB Trial, has been made available on our website, www.cervomed.com, under the heading, "Investors – Events and Presentations." Representatives of the Company may use this presentation, in whole or in part, and possibly with non-material modifications, periodically in connection with conferences, meetings, and presentations to investors, analysts and others. The information contained in the presentation is summary information that is intended to be considered in the context of the Company's filings with the U.S. Securities and Exchange Commission ("SEC") and other public announcements that the Company may make, by press release or otherwise, from time to time. The Company undertakes no duty or obligation to publicly update or revise the information contained in the presentation except as required by applicable law, although the Company may do so from time to time as its management believes is warranted. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases, or through other public disclosure. The Company makes no admission or representation as to the materiality of any information in the presentation or otherwise contained in Item 7.01 of this Current Report on Form 8-K. -- The information in this Item 7.01 is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (

01 Other Events

Item 8.01 Other Events The information set forth in the first paragraph and the information under the heading, "New Results from the Phase 2b RewinD-LB Trial," of the Company's press release referred to in Item 7.01 above is incorporated by reference into this Item 8.01 of this Current Report on Form 8-K.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 Press Release, issued October 8, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 8, 2025 CervoMed Inc. By: /s/ William Elder Name: William Elder Title: Chief Financial Officer & General Counsel

View Full Filing

View this 8-K filing on SEC EDGAR